Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Meridian
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 02 Jul 2019 This trial has been Discontinued in UK (End date: 2017-11-21) according to European Clinical Trials Database record
    • 31 Aug 2018 Biomarkers information updated
    • 24 Apr 2018 This trial has been Discontinued in Belgium (End date: 2017-11-21) according to European Clinical Trials Database record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top